Sign Up Today and Learn More About Soley Therapeutics Stock
Invest in or calculate the value of your shares in Soley Therapeutics or other pre-IPO companies through EquityZen's platform.
Soley Therapeutics Stock
Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs.
About Soley Therapeutics Stock
Founded
2018
Headquarters
San Francisco, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Soley Therapeutics Press Mentions
Stay in the know about the latest news on Soley Therapeutics
Piperazinone based modulators for the treatment of disease
patents • Feb 01, 2026
Substituted heterocyclic modulators for the treatment of disease
patents • Feb 01, 2026
Phthalazinone based modulators for the treatment of disease
patents • Feb 01, 2026
Soley Therapeutics Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling Entirely New and Accelerated Methods for Drug Discovery
businesswire • Jan 22, 2026
Soley Therapeutics Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling Entirely New and Accelerated Methods for Drug Discovery
biospace • Jan 22, 2026
Soley Therapeutics Management
Leadership team at Soley Therapeutics
Founder and Board Member
Yerem Yeghiazarians
Co-Founder, Acting CEO, and Chief Scientific Officer
Kurosh Ameri
Join now and verify your accreditation status to gain access to:
- Soley Therapeutics Current Valuation
- Soley Therapeutics Stock Price
- Soley Therapeutics Management
- Available deals in Soley Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Soley Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Soley Therapeutics Revenue and Financials
- Soley Therapeutics Highlights
- Soley Therapeutics Business Model
- Soley Therapeutics Risk Factors
- Soley Therapeutics Research Report from SACRA Research
Trading Soley Therapeutics Stock
How to invest in Soley Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Soley Therapeutics through EquityZen funds. These investments are made available by existing Soley Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Soley Therapeutics stock?
Shareholders can sell their Soley Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 430K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 51K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."